Publikationen in Zusammenarbeit mit Forschern von Hospital Clínico San Carlos de Madrid (77)

2016

  1. Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

    Leukemia Research, Vol. 40, pp. 1-9

2015

  1. Asociación de la hemoglobina Groene Hart con la hemoglobina J-París-I: primer caso en España

    Medicina Clinica, Vol. 144, Núm. 5, pp. 212-215

  2. Maternal and fetal outcomes in pregnant women with acute promyelocytic leukemia

    Annals of Hematology, Vol. 94, Núm. 8

2014

  1. Hb Cibeles [α2 CD25(B6) (Gly → Asp)]: a novel alpha chain variant causing alpha-thalassemia

    International Journal of Hematology, Vol. 100, Núm. 6, pp. 599-601

2013

  1. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

    Leukemia, Vol. 27, Núm. 10, pp. 2056-2061

  2. Association in cis of the mutations +20 (C>T) in the 5′ untranslated region and IVS-II-745 (C>G) on the β-globin gene

    Hemoglobin, Vol. 37, Núm. 2, pp. 112-118

  3. Erythrocytosis in a child due to Hb andrew-minneapolis [β144(HC1) Lys→Asn (AAG>AAT or AAC)] associated with a Spanish (δβ) ;0-thalassemia

    Hemoglobin, Vol. 37, Núm. 1, pp. 48-55

2012

  1. Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease

    Haematologica, Vol. 97, Núm. 4, pp. 616-621

  2. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

    Blood, Vol. 119, Núm. 3, pp. 687-691

  3. Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials

    American Journal of Pathology, Vol. 181, Núm. 5, pp. 1870-1878

  4. Study of three families with Hb agrinio [α29(B10)Leu→Pro, CTG>CCG (α2)] in the spanish population: Three homozygous cases

    Hemoglobin, Vol. 36, Núm. 6, pp. 526-532

  5. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA/GEM study

    Blood, Vol. 120, Núm. 8, pp. 1589-1596

2011

  1. Hb extremadura [β64(E8)Gly→Ser;β133(H11)Val→Leu]: A new molecular analysis

    Hemoglobin, Vol. 35, Núm. 4, pp. 423-427

  2. Invasive fungal infections in onco-haematology: A spanish perspective

    Revista Espanola de Quimioterapia, Vol. 24, Núm. 3, pp. 168-172

  3. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

    Blood, Vol. 118, Núm. 17, pp. 4547-4553

  4. Recomendaciones para el tratamiento de las infecciones f́ngicas invasoras causadas por hongos filamentosos en pacientes hematológicos

    Revista Espanola de Quimioterapia, Vol. 24, Núm. 4, pp. 263-270

2010

  1. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)

    Annals of Hematology, Vol. 89, Núm. 5, pp. 453-458

  2. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study

    Haematologica, Vol. 95, Núm. 11, pp. 1913-1920

  3. Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients

    Haematologica, Vol. 95, Núm. 5, pp. 745-751

  4. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: Further improvements in treatment outcome

    Blood, Vol. 115, Núm. 25, pp. 5137-5146